These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3291773)

  • 1. [Interferon-alpha].
    Furue H; Mugitani H; Hirota F; Suminaga M
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):797-803. PubMed ID: 3291773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferon-alpha in the treatment of hematologic neoplasms].
    Aulitzky W; Gastl G; Tilg H; Troppmair J; Leiter E; Geissler D; Flener R; Huber C
    Wien Med Wochenschr; 1986 Apr; 136(7-8):172-81. PubMed ID: 3524022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
    Kuzmits R; Scheithauer W; Ludwig H; Flener R
    Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intron A (interferon alfa-2b): clinical overview and future directions.
    Spiegel RJ
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):89-101. PubMed ID: 3532338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
    Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
    Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferons--its method of administration and adverse effect related to pharmacokinetics ].
    Furue H
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):186-93. PubMed ID: 6582804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS; Brandt CP; Tso CY; Laszlo J
    J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferon as a treatment tool of cancer].
    Sakurai Y
    Gan No Rinsho; 1983 May; 29(6):579-83. PubMed ID: 6876427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of interferon on various malignancies].
    Taguchi T
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):194-204. PubMed ID: 6696457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status and problems of cancer treatment with interferon].
    Ichikawa H
    Gan No Rinsho; 1983 May; 29(6):616-9. PubMed ID: 6876430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
    Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Israel L; Falcoff E; Schwab D; Pouillart P
    Cancer; 1986 Jul; 58(2):215-8. PubMed ID: 3719515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of IFN-beta in cancer therapy.
    Triozzi P; Rinehart J
    Cancer Surv; 1989; 8(4):799-808. PubMed ID: 2701728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferons in the treatment of malignancies.
    Kardamakis D
    In Vivo; 1991; 5(6):589-97. PubMed ID: 1810444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment trials with interferon beta in multiple sclerosis.
    Panitch HS
    Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris.
    Vance JC; Bart BJ; Hansen RC; Reichman RC; McEwen C; Hatch KD; Berman B; Tanner DJ
    Arch Dermatol; 1986 Mar; 122(3):272-7. PubMed ID: 3954392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
    Edwards BS; Hawkins MJ; Borden EC
    J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.
    Hand A; Pelin K; Halme M; Ekman A; Mattson M; Vallas M; Mattson K; Linnainmaa K; Husgafvel-Pursiainen K
    Anticancer Drugs; 1993 Jun; 4(3):365-8. PubMed ID: 8395259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia.
    Foon KA; Bunn PA
    Semin Oncol; 1986 Dec; 13(4 Suppl 5):35-9. PubMed ID: 3541217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.